Oncopeptides (ONCO) Stora Aktiedagarna 2026 summary

Commercial performance and market expansion

• Achieved 88% sales growth in Q4 2025 and 125% year-over-year, driven by European commercialization, with revenue projected to grow from SEK 31.6m in FY 2024 to SEK 71.2m in FY 2025.

• Full access to key European markets expected in 2026, with 100% access in Spain and Germany, and 90% in Italy.

• Adjusted investment in Germany due to slower growth, while Italy outperformed expectations.

• Over 600 patients treated with Pepaxti since EMA approval, with inclusion in updated EHA/EMN guidelines supporting adoption.

• Profitability in Europe targeted for 2027, with ongoing evaluation of direct investment versus partnerships in new markets.

Commercialization and partnerships

• Strategic focus on partnerships for Central/Eastern Europe and non-European markets, including ongoing negotiations in Japan and established presence in South Korea, Greece, MENA, Eurasia, and Africa.

• Rest of World partnerships and licensing provide upside without significant operational overhead.

• Japan identified as a high-value market with favorable regulatory conditions.

• Partnerships such as the World Orphan Drug Alliance facilitate entry into smaller or less familiar markets.

• Expansion strategy includes geographic growth, smart partnerships, and purposeful innovation.

Product innovation and clinical pipeline

• Lead product Pepaxti, a peptide-drug conjugate (PDC), offers a differentiated mechanism with high efficacy and low side effects.

• PDC platform expanded to address aggressive tumors, notably glioblastoma, leveraging a dual mechanism targeting both nuclear and mitochondrial DNA.

• Preclinical data show strong activity in glioblastoma cell cultures and effective blood-brain barrier penetration in animal models.

• Fast track status granted in Norway for a clinical study in glioblastoma, supported by a research grant from Sweden's Innovation Agency.

• Real-world data and clinical experience support the efficacy and safety of Pepaxti.